UKCA Marking Rules and UKRP Labelling Duties

1. Key takeaways

UKCA (UK Conformity Assessed) is the domestic conformity marking of the United Kingdom, governed by regulation 10 for general devices, regulation 24 for active implantable devices and regulation 36 for IVDs, with the affixing procedures set out in regulations 13, 27 and 40 respectively. Once UKCA is affixed, the name and address of the UK Responsible Person (UKRP) must appear on the product label, the outer packaging or the instructions for use; a device carrying only CE marking, without UKCA, is not subject to this mandatory requirement. The link between the marking decision and the labelling obligation is the single most consequential detail of a United Kingdom labelling project: it decides whether artwork must be redrawn, whether instruction leaflets must be reprinted and how the transition from old to new stock is managed across the supply chain.

2. Legal basis

The marking provisions are spread across the regulation, and two of them create stand-alone offences:

• UK MDR 2002 (SI 2002/618, as amended): regulation 10 (UK marking for general devices), regulation 10A (the UK(NI) indication), regulation 11 (cross-legislation marking), regulation 12 (exemptions), regulation 13 (affixing procedure), regulation 24 (marking for active implantable devices), regulation 27, regulation 36 (marking for IVDs), regulation 40; and in Part V, regulation 50 (wrongly affixing the number of a conformity assessment body) and regulation 51 (wrongly affixing the United Kingdom marking).
• Official guidance: the GOV.UK page Regulating medical devices in the UK (the section on UKRP labelling requirements).

Regulations 50 and 51 matter because they move marking from the realm of technical housekeeping into the realm of enforcement: affixing the wrong body number or the wrong national marking is itself a non-compliance, independent of any question about the underlying conformity of the device.

Where a device is covered by more than one legislative framework, regulation 11 governs how the markings combine, and the interplay should be checked for every product rather than assumed. The examination should confirm which markings the combination requires, in what order and with which accompanying identifiers, before artwork is locked. Because these combinations vary by device part — general devices, active implantable devices and IVDs each carry their own provisions — a single corporate marking policy rarely fits every product line, and the exception list deserves the same visibility as the rule itself.

3. Expert insights

Insight 1: UKCA and the UKRP labelling duty operate as a linked switch. The official guidance is explicit: the name and address of the UKRP must appear on the product label, the outer packaging or the instructions for use — but only where the UKCA marking has been affixed. A device carrying only CE marking does not need the UKRP information on its label; a device carrying both CE and UKCA must show it. This single rule determines the scope and cost of any label redesign, so the marking decision should be made together with the artwork plan, not after it, and the combination actually used for each SKU should be recorded in the item master data.

Insight 2: dual marking is permitted and common. Manufacturers supplying both the European Union and the United Kingdom markets generally adopt CE plus UKCA dual marking. In that configuration one additional rule applies: where conformity assessment was carried out by a United Kingdom approved body, the identification number of that body must appear immediately adjacent to the UKCA marking (regulation 50 prohibits wrongly affixing the number). The placement of the number is therefore not a free design choice, and the artwork review should verify adjacency, legibility and the correct body number as explicit checkpoints.

Insight 3: wrong affixing carries stand-alone sanctions. Regulation 50 and regulation 51 of Part V respectively govern the wrongful affixing of a conformity assessment body number and the wrongful affixing of the United Kingdom marking. The practical message is that the marking is not merely a technical matter but a compliance point that can directly trigger enforcement. A labelling error that would be trivial to fix in artwork can still generate regulatory attention if it reaches the market, so label changes should pass through the same controlled-document process as technical changes.

4. Practical recommendations

GRZAN recommends running a label impact assessment alongside every UKCA project: confirm the layout space needed once UKRP information is added to the label, the batches of instructions for use that must be reprinted, and the pace at which existing label stock will be consumed. For product lines holding both CE and UKCA approval, establish separate material numbers for the marking versions so that legacy labels cannot flow into the Great Britain distribution channel. The goal is a controlled transition in which old and new stock are distinguishable at the warehouse level, and the marking actually on each shipped unit matches what the registration and certification records say about it.

The assessment should also cover documentation beyond the label itself: the declaration of conformity, the certificates reproduced on websites, and any sales literature that repeats the marking. Inconsistencies between artwork, certificates and marketing materials are a common audit finding, and they are inexpensive to prevent if the marking decision is published internally as a controlled change with an effective date. A short mark-use guideline — which marks, for which devices, for which territories, with which body number — gives distributors and marketing teams a single reference and prevents well-intentioned improvisation in brochures and trade fair materials.

5. Verification checklist

• □ Whether UKCA is affixed (alone or in dual marking) has been confirmed
• □ Devices bearing UKCA carry the UKRP name and address on the label, outer packaging or instructions for use
• □ Devices assessed by a United Kingdom approved body display its number immediately adjacent to the marking
• □ Regulation 12 exemptions and regulation 11 cross-legislation situations have been checked
• □ The label revision batches and the disposition of legacy stock have been determined

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers with the following services for the United Kingdom market:

• Appointment of the UK Responsible Person (UKRP) and signature support for the letter of authorisation
• End-to-end MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee estimation
• Dual-track design for Great Britain and Northern Ireland, including UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance report submission
• Emergency response to serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

GRZAN provides end-to-end MHRA registration and compliance support for manufacturers entering the United Kingdom market, covering every stage from market entry planning through post-market obligations. For enquiries, contact info@grzanglobal.com.